BSE filing, NSE: GODAVARI. Summary written from the filing by ALFA Finder's alert engine.
Godavari Drugs Ltd: key numbers
- Share price
- ₹125.60
- Market cap
- ₹127.2 Cr
- Revenue (annual)
- ₹105.8 Cr
- Net profit (annual)
- ₹4.09 Cr
- P/E (TTM)
- 30.6×Sector 45.9×
- Promoter holding
- 40.23%+0.00% QoQ
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Godavari Drugs Ltd
All →Godavari Drugs Other Announcement
Godavari Drugs Limited changed its Corporate Identification Number (CIN) following an alteration to its Memorandum of Association's Object Clause. The Ministry of Corporate Affairs registered the change on October 16, 2026.
Godavari Drugs Debt & Borrowing: ₹34 Cr
Godavari Drugs Limited's board approved availing working capital limits of Rs. 34 Crore from ICICI Bank. The facility is within existing shareholder-approved borrowing limits.
- Value
- ₹34.00 Cr
Godavari Drugs Annual General Meeting
Godavari Drugs held its 38th Annual General Meeting on September 25, 2026, via video conferencing. Shareholders approved financial statements, director re-appointment, and object clause alteration.
Godavari Drugs Annual General Meeting
Godavari Drugs Limited will close its register of members and share transfer books from September 19 to September 25, 2026, for its 38th Annual General Meeting.
Godavari Drugs Capital Structure Change
Godavari Drugs Limited allotted 7,86,690 equity shares to the promoter category following warrant conversion. The company received Rs. 5.25 Crore, representing the final 75% payment.
- Value
- ₹5.25 Cr
Godavari Drugs Q1 FY27 Results: Net Profit ₹1.1 Cr, Up 10.0% YoY
Godavari Drugs Ltd reported revenue from operations of ₹28 Cr (+17.6% YoY) and net profit of ₹1.1 Cr (+10.0% YoY) for Q1 FY27.
- Key figure
- Net profit ₹1.1 Cr · +10.0% YoY
Other board meeting outcome announcements
All →Emergent Industrial Solutions Board Meeting Outcome
Emergent Industrial Solutions reconstituted its four board committees, reassigning existing directors across Audit, Nomination, Stakeholders Relationship, and CSR roles. This is routine governance with no financial impact.
Winsol Engineers Board Meeting Outcome
Winsol Engineers' board approved AoA changes to allow voluntary dividend waiver and postal ballot logistics. All decisions are routine governance matters with no material business impact.
Nirlon Board Meeting Outcome
Nirlon Ltd's board approved a modification to its Dividend Distribution Policy on November 2, 2026. This is a routine governance update with no dividend declared or cash impact.
Novus Loyalty Board Meeting Outcome
Novus Loyalty's board approved voluntary quarterly financial reporting from the December 2026 quarter, enhancing transparency beyond the mandatory half-yearly SME disclosure requirement.
Bharat Global Developers Board Meeting Outcome
Board approved shifting registered office within Ahmedabad and postponed Q1 and H1 FY27 financial results to a subsequent meeting. No material business decision was taken.
Pasari Spinning Mills Board Meeting Outcome
Pasari Spinning Mills reconstituted its Audit, NRC and SRC committees after an independent director resigned and Ms. Bhavna Agrawal was appointed. The change takes effect from the 30 October 2026 board meeting.